San Francisco, CA (October 23, 2023) - RCE Technologies, Inc. had the opportunity to go center stage and present an overview of the company's innovative technology along with late breaking insights from recently conducted studies around continuous trending of cardiac injury biomarkers. These insights gained extend the clinical value of the wearable technology that was presented at the ACC-Late Breaking Clinical Trials by Dr.Partho Sengupta earlier this year, where he cast the vision of utility in trending continuous biomarkers.
RCE continues its scientific and clinical series of validation to advance its novel technology towards patient care.
RCE.ai, an AI based med tech company works towards the early detection of heart attacks. We have re-imagined the way cardiac proteins are monitored in the blood using a non-invasive transdermal technique. The point of care trending of the composite of acute cardiac injury biomarkers can empower emergency medicine physicians and cardiologists in the early assessment and appropriate risk stratification of patients presenting with chest pain. The company is actively conducting clinical validation trials and undertaking premarket efforts.